PURPOSE OF THE STUDY The purpose of this study is to learn if a study drug called Guanfacine is helpful in treating hyperactivity and impulsiveness in children with PDD. Guanfacine is widely used for the treatment of hyperactivity and impulsiveness in this population, but has not been carefully studied. It is approved by the FDA for the treatment of hypertension, but a long-acting formula has recently been approved to treat Attention-Deficit/Hyperactivity Disorder in children. This study will also determine if adding methylphenidate (MPH) on top of guanfacine will improve hyperactive and impulsive symptoms in children who are not responding positively to guanfacine alone. MPH is FDA approved for the treatment of these symptoms in children PARTICIPANTS AND STUDY DESIGN Eligible participants must have been diagnosed with a pervasive developmental disorder and have problems with hyperactivity and impulsivity. This study is sponsored by the National Institute of Mental Health and will last for up to 16 weeks. Children ages 5-14 will be included in this national study, and approximately 45 from UCLA. STUDY COORDINATOR Jenny Cowen, Ph.D. She can be reached at (310) 825-6170.
Originally created: 5 Mar 2012 Current author: Dr. Candace J. Wi...
Jane & Terry Semel Institute for Neuroscience & Human Behavior
760 Westwood Plaza
Los Angeles, CA 90095
UCLA Health System School of Medicine
(c) UC Regents 2011 Privacy Notice
Help Sitemap A-Z index